ERS Genomics has announced the signing of a license agreement with Otsuka Pharmaceutical. The license grants Otsuka access to CRISPR/Cas9 genome editing technology for its internal research and development initiatives to address areas of unmet medical need.
ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmannuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“We are extremely pleased to be able to provide Otsuka with access to the CRISPR/Cas9 license. We hope this brings significant value to Otsuka as it applies the technology to its internal programs,” Eric Rhodes, CEO of ERS Genomics, said.
Financial details of the agreement are not disclosed.